alfapump® DSR study in Heart Failure patients with persistent congestion Ghent, BELGIUM – 1 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the SAHARA DESERT study. Interim...Read More